Selective NR2B antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KING DALTON, KARAGEORGE GEORGE N, IWUAGWU CHRISTIANA I, MACOR JOHN E, OLSON RICHARD E
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	KING DALTON KARAGEORGE GEORGE N IWUAGWU CHRISTIANA I MACOR JOHN E OLSON RICHARD E
description	The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US8841301B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US8841301B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US8841301B23</originalsourceid><addsrcrecordid>eNrjZJAKTs1JTS7JLEtV8AsyclJIzCtJTM_PyywuKeZhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGhwRYWJobGBoZORsZEKAEA5WkiaA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Selective NR2B antagonists</title><source>esp@cenet</source><creator>KING DALTON ; KARAGEORGE GEORGE N ; IWUAGWU CHRISTIANA I ; MACOR JOHN E ; OLSON RICHARD E</creator><creatorcontrib>KING DALTON ; KARAGEORGE GEORGE N ; IWUAGWU CHRISTIANA I ; MACOR JOHN E ; OLSON RICHARD E</creatorcontrib><description>The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140923&DB=EPODOC&CC=US&NR=8841301B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140923&DB=EPODOC&CC=US&NR=8841301B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KING DALTON</creatorcontrib><creatorcontrib>KARAGEORGE GEORGE N</creatorcontrib><creatorcontrib>IWUAGWU CHRISTIANA I</creatorcontrib><creatorcontrib>MACOR JOHN E</creatorcontrib><creatorcontrib>OLSON RICHARD E</creatorcontrib><title>Selective NR2B antagonists</title><description>The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJAKTs1JTS7JLEtV8AsyclJIzCtJTM_PyywuKeZhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGhwRYWJobGBoZORsZEKAEA5WkiaA</recordid><startdate>20140923</startdate><enddate>20140923</enddate><creator>KING DALTON</creator><creator>KARAGEORGE GEORGE N</creator><creator>IWUAGWU CHRISTIANA I</creator><creator>MACOR JOHN E</creator><creator>OLSON RICHARD E</creator><scope>EVB</scope></search><sort><creationdate>20140923</creationdate><title>Selective NR2B antagonists</title><author>KING DALTON ; KARAGEORGE GEORGE N ; IWUAGWU CHRISTIANA I ; MACOR JOHN E ; OLSON RICHARD E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US8841301B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2014</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>KING DALTON</creatorcontrib><creatorcontrib>KARAGEORGE GEORGE N</creatorcontrib><creatorcontrib>IWUAGWU CHRISTIANA I</creatorcontrib><creatorcontrib>MACOR JOHN E</creatorcontrib><creatorcontrib>OLSON RICHARD E</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KING DALTON</au><au>KARAGEORGE GEORGE N</au><au>IWUAGWU CHRISTIANA I</au><au>MACOR JOHN E</au><au>OLSON RICHARD E</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Selective NR2B antagonists</title><date>2014-09-23</date><risdate>2014</risdate><abstract>The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US8841301B2
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title	Selective NR2B antagonists
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T12%3A34%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KING%20DALTON&rft.date=2014-09-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS8841301B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true